News|Articles|November 19, 2026

LIB-01 enters phase 2b development for erectile dysfunction

Author(s)Hannah Clarke
Listen
0:00 / 0:00

Key Takeaways

  • An adaptive, two-part phase 2b design will identify a highest evaluable dose in Part I, then proceed to Part II, with Part I expected to finish in Q1 2027.
  • Repeated monthly dosing across 25 mg, 50 mg, and a selected higher dose aims to match a proposed durable pharmacology distinct from on-demand or daily PDE5 inhibitors.
SHOW MORE

The results are intended to inform dose selection ahead of a potential phase 3 program.

Dicot Pharma has initiated a phase 2b clinical trial evaluating LIB-01, an investigational oral treatment for erectile dysfunction (ED), with the goal of identifying an appropriate dose for further clinical development.1 The study will evaluate the effects of repeated, monthly dosing across 3 dose levels, with results intended to inform dose selection ahead of a potential phase 3 program.

The study's initiation follows phase 2a findings suggesting that LIB-01 may improve erectile function for several weeks after a short treatment course.2 Unlike currently available phosphodiesterase type 5 (PDE5) inhibitors, which are generally administered on demand or daily, LIB-01 is being developed around a proposed mechanism that could produce more sustained effects following intermittent dosing.

"The start of our clinical study is an important milestone for the company,” said Elin Trampe, CEO of Dicot Pharma, in the company's news release.1 “The phase 2b study is tailored to LIB-01's unique pharmacology and response profile, and we now look forward to taking the next step in the development toward a new treatment option for men and couples affected by erectile dysfunction.”

Phase 2b study design

The phase 2b study will use an adaptive design and is expected to enroll at least 200 men across sites in the US and Europe. Unlike the phase 2a study, which evaluated a single 3-day course of treatment, the new study will investigate LIB-01 following repeated, monthly dosing. The trial will evaluate 3 dose levels: 25 mg, 50 mg, and a higher dose to be selected during the initial portion of the study. The 25-mg and 50-mg doses were selected based on the phase 2a findings.

The study is divided into 2 parts. Part I, which has now begun in the US following the first screening visit, will determine the highest dose to be evaluated in Part II. Dicot Pharma expects Part I to conclude during the first quarter of 2027, with Part II expected to begin afterward.

The primary efficacy end point is change from baseline in the erectile function domain of the International Index of Erectile Function (IIEF-EF) questionnaire at week 12. The study will include men across all severities of ED, expanding the population evaluated in the earlier phase 2a study, which enrolled men with mild to moderate ED.

Phase 2a findings provide rationale for further evaluation

The phase 2b program builds on a randomized, placebo-controlled phase 2a study (NCT06703840) that enrolled 156 men with mild to moderate ED (IIEF‑EF 11 to 25). Participants received LIB-01 at doses of 10 mg, 25 mg, or 50 mg, or placebo, once daily for 3 days, followed by 8 weeks of observation. The primary efficacy end point was change in IIEF-EF score at week 4.

According to results presented at the 2026 Sexual Medicine Society of North America Annual Meeting, improvements in erectile function were observed across the treatment groups.2 The 50-mg group demonstrated an 8.5-point improvement from baseline at week 4, which exceeded the 5-point threshold for clinical significance (P = .11 vs placebo). At week 4, 31% of patients in the 50 mg LIB-01 cohort achieved normal erectile function IIEF‑EF greater than 25) compared with 0% with placebo (P = .04).

At week 8, the improvement was maintained in the 2 higher-dose groups. Among participants with moderate ED, the 50-mg group demonstrated a 7.5-point improvement from baseline (P = .06 vs placebo). A prespecified pooled analysis of the 25-mg and 50-mg groups demonstrated a 6.5-point improvement from baseline compared with placebo (P = .03).

According to the study authors, LIB-01 was well-tolerated, with adverse events generally mild and transient and occurring primarily during initial dosing. Mild gastrointestinal symptoms were the most common adverse event reported.

_____

REFERENCES

1. Dicot Pharma initiates phase 2b clinical study in erectile dysfunction. News release. Dicot Pharma. November 18, 2026. Accessed November 19, 2026. https://www.dicotpharma.com/en/press/press-releases/?slug=dicot-pharma-initiates-phase-2b-clinical-study-in-erectile-dysfunction

2. Rosen RC, Giuliano F, Padma-Nathan H, Gauffin C. LIB-01: Part II - A Novel First‑in‑Class Oral Investigational Therapy for Erectile Dysfunction with Demonstrated Clinically Meaningful Improvements In Erectile Function and Duration of Action up to 8 Weeks. Presented at: 27th Annual Fall Scientific Meeting of SMSNA. October 8-11, 2026. Orlando, Florida. Abstract 077


Related to this article

Rethinking Testosterone Therapy After the FDA Label Revisions
Expert urologists examine how TRAVERSE data and an FDA expert panel prompted proposed label revisions for testosterone therapy as well as what narrowed cardiovascular, prostate, and age-related restrictions mean for evaluating and treating testosterone deficiency.